Nanoligent
PrivateLast Round
Grant
Jun 19, 2025
Total Funding Raised
$2.71M
Company Overview
Nanoligent is a biotechnology company that develops nanotechnology-based anti-cancer treatments intended to treat different types of metastatic cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nanoligent Comps
Public and private peers based on sector, stage, and business model.
Nanoligent Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 19, 2025 | ||||
| Accelerator | Nov 21, 2023 | ||||
| Seed | Sep 27, 2022 | ||||
| Grant | Dec 13, 2018 |
Key People
Founding team and executive leadership
Nanoligent Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Avanteca Partners | Seed |
| Italian Angels for Growth | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 18, 2026
Monthly visitors grew 243% MoM.
- Jun 19, 2025
Won the Santander X Award 2025 for Best University Start-up.
Nanoligent Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Nanoligent's valuation, stock price, and market status.
